We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Pfizer Inc. (PFE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) , Cisco Systems, Inc. (CSCO - Free Report) and ConocoPhillips (COP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Alphabet, Pfizer and Uber
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Pfizer and Uber Technologies. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Alphabet shares have outperformed the S&P 500 over the past year (+39.1% vs. +17.9%). The Zacks analyst believes that the expanding data centers will continue to bolster the company’s presence in the cloud space. Further, major updates in the search segment are enhancing the search results, which is a major positive.
Alphabet reported strong fourth-quarter earnings. The search, cloud and YouTube businesses remained strong in the quarter. The company’s strengthening cloud unit aided substantial revenue growth.
Moreover, Google’s robust mobile search is gaining solid momentum. Additionally, strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. However, the company’s growing litigation issues and increasing expenses might hurt profitability.
Shares of Pfizer have lost -8.9% in the last six months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +4.1%. The Zacks analyst believes that currency headwinds and pricing pressure are key top-line headwinds.
However, Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Its COVID-19 vaccine candidate, developed in record time, is now approved for emergency use in several countries. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
Uber shares have gained +29% over the past three months against the Zacks Internet Services industry’s rise of +11.6%. The Zacks analyst believes that Uber’s delivery business is witnessing a boom with online order volumes from homebound customers surging.
In such a scenario, the acquisition of Postmates, which expands its delivery unit, provides a further boost. Additionally, the company has entered into a deal to acquire alcohol delivery startup Drizly Inc. for $1.1 billion. The acquisition is expected to close within the first half of 2021.
However, a significant downturn in the Mobility business is concerning. Although ride volumes have improved from the April lows, it is way below 2019 levels. Due to this rides weakness, Uber expects to become profitable in 2021 instead of 2020, as was anticipated previously.
Other noteworthy reports we are featuring today include Cisco Systems and ConocoPhillips.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Google, Pfizer, Uber, Cisco Systems and ConocoPhillips
For Immediate Release
Chicago, IL – February 8, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Alphabet Inc. (GOOGL - Free Report) , Pfizer Inc. (PFE - Free Report) , Uber Technologies, Inc. (UBER - Free Report) , Cisco Systems, Inc. (CSCO - Free Report) and ConocoPhillips (COP - Free Report) .
Here are highlights from Friday’s Analyst Blog:
Top Stock Reports for Alphabet, Pfizer and Uber
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alphabet, Pfizer and Uber Technologies. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Alphabet shares have outperformed the S&P 500 over the past year (+39.1% vs. +17.9%). The Zacks analyst believes that the expanding data centers will continue to bolster the company’s presence in the cloud space. Further, major updates in the search segment are enhancing the search results, which is a major positive.
Alphabet reported strong fourth-quarter earnings. The search, cloud and YouTube businesses remained strong in the quarter. The company’s strengthening cloud unit aided substantial revenue growth.
Moreover, Google’s robust mobile search is gaining solid momentum. Additionally, strong focus on innovation of AI techniques and the home automation space should aid business growth in the long term. However, the company’s growing litigation issues and increasing expenses might hurt profitability.
(You can read the full research report on Alphabet here >>>)
Shares of Pfizer have lost -8.9% in the last six months against the Zacks Large-Cap Pharmaceuticals industry’s gain of +4.1%. The Zacks analyst believes that currency headwinds and pricing pressure are key top-line headwinds.
However, Pfizer expects strong growth of key brands like Ibrance, Inlyta and Eliquis to drive sales. Its COVID-19 vaccine candidate, developed in record time, is now approved for emergency use in several countries. Pfizer boasts a sustainable pipeline with multiple late-stage programs that can drive growth.
(You can read the full research report on Pfizer here >>>)
Uber shares have gained +29% over the past three months against the Zacks Internet Services industry’s rise of +11.6%. The Zacks analyst believes that Uber’s delivery business is witnessing a boom with online order volumes from homebound customers surging.
In such a scenario, the acquisition of Postmates, which expands its delivery unit, provides a further boost. Additionally, the company has entered into a deal to acquire alcohol delivery startup Drizly Inc. for $1.1 billion. The acquisition is expected to close within the first half of 2021.
However, a significant downturn in the Mobility business is concerning. Although ride volumes have improved from the April lows, it is way below 2019 levels. Due to this rides weakness, Uber expects to become profitable in 2021 instead of 2020, as was anticipated previously.
(You can read the full research report on Uber here >>>)
Other noteworthy reports we are featuring today include Cisco Systems and ConocoPhillips.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.